Peptides for Weight Loss Beyond GLP-1: AOD-9604, Tesofensine, and What Works

GLP-1 medications dominate the Filipino weight-loss conversation in 2026, and for good reason: tirzepatide, semaglutide, and liraglutide have the strongest published evidence base in the category. But several other peptides and small molecules are marketed for weight loss in Filipino biohacker and aesthetic communities. Some have meaningful evidence. Some have plausible mechanism but thin trial support. Some are commercial fiction.

This guide takes an evidence-rated tour of the secondary weight-loss peptide market: AOD-9604 (the modified HGH fragment), tesofensine (the Danish-developed monoamine reuptake inhibitor), MOTS-c (the mitochondrial-derived peptide), and several smaller categories. We honestly assess what each does, where each fits alongside GLP-1 medications, and the quality concerns that affect each.

For the broader pillar context, see our Tirzepatide Philippines complete guide. For the broader research-peptide landscape, see peptide therapy in the Philippines. For compounded peptide quality issues generally, see compounded tirzepatide and semaglutide in the Philippines.

The framing question

Why look beyond GLP-1 medications? A few reasons Filipino users explore secondary weight-loss peptides:

1. GLP-1 plateau. Some users on tirzepatide or semaglutide reach a weight-loss plateau before their goal and look for additional tools.
2. GLP-1 intolerance. Some users cannot tolerate the gastrointestinal side effects of GLP-1 medications and seek alternatives.
3. Cost. branded tirzepatide at PHP 30,000 per month is unaffordable for many Filipino users; cheaper alternatives are attractive.
4. Specific target effects. Some peptides target specific mechanisms (fat oxidation, mitochondrial function) that GLP-1 medications do not address directly.
5. Stacking. Some users combine GLP-1 medications with secondary peptides for synergistic effect, with mixed evidence support.

The honest framing for users considering this category: GLP-1 medications produce the largest evidence-based weight-loss effect available outside surgery. Secondary peptides offer smaller and less well-characterised effects. The decision should be informed by realistic expectations.

AOD-9604

AOD-9604 (anti-obesity drug-9604, also called LAB GHRP) is a modified C-terminal fragment of human growth hormone. The fragment retains some lipolytic (fat-breakdown) activity of the parent molecule without the full GH effects.

Mechanism:

• Stimulates fat oxidation through beta-3 adrenergic pathways.
• Does not significantly raise IGF-1.
• Does not promote muscle growth (unlike full HGH).
• Theoretical preferential effect on visceral and abdominal fat.

Evidence:

• Phase 2 trials by the original developer in early 2000s showed modest effects on body fat in obese subjects.
• Subsequent commercial development was discontinued; the molecule never reached Phase 3 or regulatory approval.
• Marketed extensively in research-peptide channels with claims that exceed the trial data.

Honest evidence rating: tier C. Modest effects in early trials, never confirmed in larger trials. Mechanism is plausible. Effect magnitude is small.

Filipino market: available through grey-market peptide channels, typically as 2 to 5 mg vials at PHP 2,000 to 5,000.

Practical recommendation: AOD-9604 is unlikely to produce dramatic weight-loss effects standalone. May have a modest role as a stack component for users seeking specific fat-loss mechanism. Evidence does not support claims of revolutionary weight-loss outcomes.

Tesofensine

Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) developed by a Danish pharmaceutical developer (Denmark) originally for Parkinson's and Alzheimer's. Phase 2 trials for these indications were unsuccessful, but the molecule produced significant weight loss as a side effect, leading to repurposing studies for obesity.

Mechanism:

• Inhibits reuptake of serotonin, noradrenaline, and dopamine.
• Reduces appetite through central nervous system action.
• Increases energy expenditure modestly.
• Different mechanism from GLP-1 medications; could theoretically combine without redundancy.

Evidence:

• Phase 2 obesity trial (Astrup et al., 2008) showed approximately 12% body weight reduction at 1 mg daily over 24 weeks.
• The effect size was larger than what was achievable with then-available weight-loss medications.
• Phase 3 development stalled due to cardiovascular safety concerns (modest blood-pressure increases).
• Approved in Mexico in 2022 as branded tesofensine combination (combination with metoprolol to address cardiovascular concerns); not approved in US, EU, or Philippines.

Honest evidence rating: tier B for weight loss in trials; tier C for safety profile and long-term outcomes.

Filipino market: available through grey-market channels, typically as compounded tablets or capsules. Prices vary; PHP 4,000 to 12,000 per month is typical.

Practical recommendation: tesofensine has real weight-loss effects but cardiovascular safety concerns limit appropriate use. Cardiovascular monitoring (blood pressure, heart rate, and ideally periodic ECG) is essential during use. Filipino users considering tesofensine should consult a clinician comfortable with the cardiovascular monitoring requirements. Risk-benefit balance is less favourable than well-monitored GLP-1 medications.

MOTS-c

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondrial-derived peptide discovered in the early 2010s. The peptide is encoded by mitochondrial DNA and has roles in metabolic regulation.

Mechanism:

• Activates AMPK, the cellular energy sensor.
• Improves insulin sensitivity in animal models.
• Increases fat oxidation.
• Supports mitochondrial biogenesis.
• Effects extend beyond weight loss to broader metabolic health markers.

Evidence:

• Animal studies show favourable metabolic effects including reduced body fat, improved insulin sensitivity, and increased exercise capacity.
• Limited human trials. The few small studies show some metabolic improvements.
• Not approved for any indication.
• Marketed enthusiastically in biohacker communities for "metabolic restoration" and longevity claims that exceed the trial data.

Honest evidence rating: tier C for weight loss specifically; potentially tier B for broader metabolic health support, but human evidence remains thin.

Filipino market: available through research-peptide channels, typically as 5 mg vials at PHP 3,000 to 7,000.

Practical recommendation: MOTS-c has interesting mechanism and some promising animal data. Human evidence for weight loss is too thin to support strong recommendations. May have a role for users prioritising metabolic health and exercise performance over pure weight loss.

5-amino-1MQ

5-amino-1-methylquinolinium (5-amino-1MQ) is a small molecule inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase). NNMT is highly expressed in adipose tissue in obesity; inhibition theoretically reduces fat-cell expansion.

Mechanism:

• NNMT inhibition.
• Animal studies show reduced fat accumulation and improved metabolic markers.

Evidence:

• Animal data only.
• No published human clinical trials.
• Strong biohacker community interest based on the mechanism.

Honest evidence rating: tier D for human application. Promising preclinical mechanism with no clinical evidence.

Filipino market: available through some research-chemical vendors. Pricing varies.

Practical recommendation: experimental at best. Filipino users should treat 5-amino-1MQ as preclinical research material rather than a usable weight-loss compound.

Other compounds in the secondary weight-loss space

Cagrilintide: the manufacturer's amylin analogue, in development for combination with semaglutide (investigational cagrilintide-semaglutide combination). Phase 3 data is pending. Not yet on the grey market significantly.

Setmelanotide (branded melanocortin therapy): melanocortin-4 receptor agonist approved for specific genetic obesity syndromes. Very expensive; specialty indication only. Not relevant for general weight-loss use.

SR-9011 and other SARMs: not technically weight-loss peptides but sometimes marketed in adjacent communities. Different category with their own quality and safety considerations.

Bremelanotide (PT-141): marketed primarily for sexual function but with some peripheral metabolic claims. Effect on weight loss is minimal.

Frag 176-191: another HGH fragment with weight-loss claims, similar to AOD-9604 in concept and evidence.

How these compounds compare to GLP-1 medications

The pattern: GLP-1 medications have the largest documented effects in human trials. Secondary compounds offer smaller effects with thinner evidence.

Quality and authentication concerns

Each compound in this category has its own quality issues:

AOD-9604: variable quality across vendors. Underdosing is common. Some products test at 30 to 60% of label.

Tesofensine: most Filipino-market tesofensine is compounded into tablets or capsules. Active ingredient concentration is highly variable. Purity is often below pharmaceutical-grade standards.

MOTS-c: research-grade peptide with quality similar to other research peptides. Underdosing and degradation are common.

5-amino-1MQ: research-chemical category with minimal quality control. Authentication is particularly difficult.

For all categories, lab verification is the only objective answer. Lumen Labs runs HPLC purity, LC-MS identity, and quantitation on submitted samples. The output is a certificate of analysis.

How these compounds fit alongside GLP-1 medications

For Filipino users on tirzepatide or semaglutide who are considering adding a secondary weight-loss peptide:

Reasonable additions (with caveats):

• AOD-9604 for users wanting additional fat-oxidation support without GH effects.
• MOTS-c for users prioritising metabolic health alongside weight loss.

Approach with caution:

• Tesofensine, due to cardiovascular monitoring needs.
• Stimulant-based fat burners that compound cardiovascular load.

Generally not recommended:

• 5-amino-1MQ and similar preclinical compounds without clinical evidence.
• Combining multiple unproven compounds simultaneously, which compounds quality and side-effect uncertainty.

The pragmatic guidance: optimise GLP-1 dose and lifestyle factors first. Secondary peptides typically produce small additional effects that may not justify the cost and quality uncertainty.

Bottom line on weight-loss peptides beyond GLP-1

The secondary weight-loss peptide market includes some compounds with real evidence (tesofensine), some with modest mechanism support (AOD-9604, MOTS-c), and some with preclinical-only data (5-amino-1MQ). None match GLP-1 medications for documented effect magnitude.

For Filipino users seeking weight-loss tools beyond GLP-1, the highest-leverage strategy is optimising GLP-1 medication dose, lifestyle, and adherence rather than stacking unproven secondary compounds. Where secondary compounds have a role, lab verification of quality and authentication is the harm-reduction step.

Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. Most compounds discussed in this article are not FDA Philippines registered for human weight-loss use. Consult a qualified Philippine licensed physician before any weight-loss compound use.